VYNE Therapeutics (VYNE) Gets a Buy from TD Cowen

Tip Ranks
2025.11.07 17:56
portai
I'm PortAI, I can summarize articles.

TD Cowen analyst Stacy Ku has maintained a Buy rating on VYNE Therapeutics, setting a price target of $2.00. Ku, who focuses on the Healthcare sector, has an average return of 13.1% and a 60.34% success rate on recommended stocks. The current analyst consensus on VYNE Therapeutics is a Moderate Buy, with an average price target also at $2.00.

TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics today and set a price target of $2.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Ku covers the Healthcare sector, focusing on stocks such as BioCryst, KalVista Pharmaceuticals, and LENZ Therapeutics. According to TipRanks, Ku has an average return of 13.1% and a 60.34% success rate on recommended stocks.

Currently, the analyst consensus on VYNE Therapeutics is a Moderate Buy with an average price target of $2.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.